AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Set up an RSS feed
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Brown University Child and Adolescent Psychopharmacology Update back issues
|
|
Medications for ADHD Show Similarities and Differences in Action
November 1, 2012... The stimulant medication methylphenidate and the non-stimulant drug atomoxetine show both common and divergent neurophysiologic actions in brain regions associated with attention-deficit hyperactivity disorder (ADHD), according to a study using functional magnetic resonance imaging (MRI)...
Guanfacine XR as Part of ADHD Therapy Found Cost-Effective
November 1, 2012... Adding extended-release guanfacine to stimulant treatment for children and adolescents with attention-deficit hyperactivity disorder (ADHD) appears to be a cost-effective option for youths with inadequate response to stimulant monotherapy, a new economic analysis indicates. Based on 2005...
Can Atomoxetine and Stimulants Be Safely and Effectively Combined?
November 1, 2012... Both stimulants and atomoxetine (ATMX) have been proven effective as monotherapy for attention-deficit hyperactivity disorder (ADHD) and are used as first-line treatment agents. However, given the complexity and heterogeneity of ADHD symptomatology as well as the possibility of comorbidity,...
Swedish Study Finds Increase in ADHD Drug Use and Higher Discontinuation Rates
November 1, 2012... A Swedish study exploring the prevalence and discontinuation of dispensed medications for attention-deficit hyperactivity disorder (ADHD) drugs between 2006 and 2009 found a substantial increase in prescribing during that time, with an average yearly increase of 34%. There was a greater...
Atomoxetine Reduces Symptoms in Multiple Categories
November 1, 2012... A study of 8 weeks of atomoxetine treatment for children ages 6 to 12 with attention-deficit hyperactivity disorder (ADHD) has found that the selective norepinephrine reuptake inhibitor improved patients' executive function, inhibitory control, and hyperactivity. The study's lead author says...